
Nuvation Bio (NUVB) Stock Forecast & Price Target
Nuvation Bio (NUVB) Analyst Ratings
Bulls say
Nuvation Bio is a promising biopharmaceutical company with a strong pipeline and a diversified revenue stream through out-licensing agreements. They have a promising candidate, taletrectinib, for the treatment of ROS1+ NSCLC, and other potential candidates in clinical development. Their financials show positive growth potential, and potential risks include negative clinical data, competition in the market, and physician adoption. Overall, the company's strong potential and strategic initiatives make them a compelling investment opportunity.
Bears say
Nuvation Bio is a relatively new biopharmaceutical company with a limited track record and a small pipeline focused primarily on one product for a specific type of lung cancer. While their partnership with Japan does provide some revenue opportunities, the success of their product Ibtrozi and ongoing development for safusidenib in mIDH1 glioma is the main driver of their valuation, which carries significant commercialization and regulatory risks.
This aggregate rating is based on analysts' research of Nuvation Bio and is not a guaranteed prediction by Public.com or investment advice.
Nuvation Bio (NUVB) Analyst Forecast & Price Prediction
Start investing in Nuvation Bio (NUVB)
Order type
Buy in
Order amount
Est. shares
0 shares